ERBB2 and breast carcinoma: Inconsistent with our research, a previous research has shown that, in HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, high grades of TILs in tissues before NAT were associated with a significant improvement in the pCR rate (39).